Phase II Trial of Dual LAG-3–PD-1 Inhibition With Neoadjuvant Relatlimab + Nivolumab in Resectable Stage III Melanoma

A downloadable slideset from Clinical Care Options (CCO) developed by 3 expert faculty on the impact of new data on treatment algorithms in melanoma.

Jeffrey S. Weber, MD, PhD
Program Director Allison Betof Warner, MD, PhD Hussein Tawbi, MD Released: September 10, 2021

A downloadable slideset from Clinical Care Options (CCO) developed by 3 expert faculty on the changing therapeutic landscape in advanced melanoma.

Allison Betof Warner, MD, PhD Hussein Tawbi, MD Jeffrey S. Weber, MD, PhD Released: September 7, 2021

Global perspectives of key novel combination studies presented at ASCO 2021 from international experts in solid tumors from Clinical Care Options (CCO)

Dirk Arnold, MD, PhD Prof Isabelle Ray-Coquard, MD, PhD Egbert F. Smit, MD, PhD Released: August 5, 2021

This commentary by Jeffrey Weber, MD, PhD, offers expert insight on recent clinical data with neoadjuvant therapy in melanoma from Clinical Care Options (CCO)

Jeffrey S. Weber, MD, PhD Released: July 15, 2021